Cimzia expiry date?

When does Cimzia’s main patent expire?
The principal U.S. patent protecting certolizumab pegol (Cimzia)—U.S. patent 7,476,792—expires in 2023. This expiration clears the way for biosimilar development under current regulatory rules. [1]

Are any other patents still in force?
Several secondary patents covering formulation, delivery devices, and specific therapeutic indications expire in 2024 or 2025. These do not preclude the introduction of generic‑like biosimilars but can delay their availability. [2]

When can biosimilars enter the market?
In the United States, the FDA allows a biosimilar to be approved one year after the original product’s patent expiry, provided no supplemental exclusivities exist. With the main patent ending in 2023, the earliest a biosimilar could be launched is 2024, assuming the sponsor files the application promptly. [3]

What will happen to prices once patents expire?
Historically, the loss of exclusive rights for biologics can reduce prices by 20‑40 %. Early biosimilar entries tend to keep prices competitive, especially for chronic conditions like rheumatoid arthritis and Crohn’s disease, where multiple therapies exist. [4]

Is the drug’s shelf life the same as its patent expiration?
No. The shelf life refers to the time the medication remains stable and safe when stored under recommended conditions. Manufacturers typically list a 2‑ to 3‑year expiry on the bottle, independent of patent status.

Who owns the patents for Cimzia?
Novartis holds the U.S. patents on certolizumab pegol. The company also holds related patents in the EU and other major markets. The patent portfolio is managed through Novartis’ intellectual‑property division. [5]

Sources
[1] DrugPatentWatch.com – Certolizumab Pegol Patent Expiration.
[2] DrugPatentWatch.com – Secondary Patent Expirations.
[3] U.S. Food & Drug Administration – Biosimilar Pathway.
[4] MarketWatch – Biologic Price Trends Post‑Patent.
[5] Novartis – Patents and Intellectual Property Overview.